Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
60.020USD
-0.560-0.92%
Close 07-31 16:00（ET）Quotes delayed by 15 min
11.60BMarket Cap
43.02P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of BioMarin Pharmaceutical Inc is 8.21, ranking 50 out of 155 in the Pharmaceuticals industry. The average price target is 91.50, with a high of 122.00 and a low of 55.00.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
89.426
Target Price
+45.72%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
BioMarin Pharmaceutical Inc
BMRN
27
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is BioMarin Pharmaceutical Inc's expected revenue for the next quarter?
BioMarin Pharmaceutical Inc's expected revenue is 926.91M.
What is BioMarin Pharmaceutical Inc's price target?
Analysts forecast that BioMarin Pharmaceutical Inc's price target is USD 91.50, with the highest forecast at USD 122.00 and the lowest forecast at USD 55.00.
How have BioMarin Pharmaceutical IncBMRN's recent earnings per share performed?
The market expectation was USD 0.55, while BioMarin Pharmaceutical IncBMRN's earnings per share (EPS) for the previous quarter was USD -0.24. EPS for the next quarter is expected at USD 0.69.
What is the analyst rating for BioMarin Pharmaceutical Inc?
Based on the ratings of BioMarin Pharmaceutical Inc's stock from 27 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.